These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 36897777)

  • 1. FAM193A is a positive regulator of p53 activity.
    Szwarc MM; Guarnieri AL; Joshi M; Duc HN; Laird MC; Pandey A; Khanal S; Dohm E; Bui AK; Sullivan KD; Galbraith MD; Andrysik Z; Espinosa JM
    Cell Rep; 2023 Mar; 42(3):112230. PubMed ID: 36897777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression.
    Palani CD; Beck JF; Sonnemann J
    Invest New Drugs; 2012 Feb; 30(1):25-36. PubMed ID: 20680659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
    Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
    Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill.
    Xie X; He G; Siddik ZH
    Mol Pharmacol; 2020 Apr; 97(4):237-249. PubMed ID: 32063580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
    Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
    Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDK9 activity is critical for maintaining MDM4 overexpression in tumor cells.
    Štětková M; Growková K; Fojtík P; Valčíková B; Palušová V; Verlande A; Jorda R; Kryštof V; Hejret V; Alexiou P; Rotrekl V; Uldrijan S
    Cell Death Dis; 2020 Sep; 11(9):754. PubMed ID: 32934219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The long and the short of it: the MDM4 tail so far.
    Haupt S; Mejía-Hernández JO; Vijayakumaran R; Keam SP; Haupt Y
    J Mol Cell Biol; 2019 Mar; 11(3):231-244. PubMed ID: 30689920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S-MDM4 mRNA overexpression indicates a poor prognosis and marks a potential therapeutic target in chronic lymphocytic leukemia.
    Liu L; Fan L; Fang C; Zou ZJ; Yang S; Zhang LN; Li JY; Xu W
    Cancer Sci; 2012 Dec; 103(12):2056-63. PubMed ID: 22937789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors.
    Vaseva AV; Yallowitz AR; Marchenko ND; Xu S; Moll UM
    Cell Death Dis; 2011 May; 2(5):e156. PubMed ID: 21562588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: a Brownian dynamics study.
    ElSawy KM; Verma CS; Joseph TL; Lane DP; Twarock R; Caves LS
    Cell Cycle; 2013 Feb; 12(3):394-404. PubMed ID: 23324352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors.
    Howard TP; Arnoff TE; Song MR; Giacomelli AO; Wang X; Hong AL; Dharia NV; Wang S; Vazquez F; Pham MT; Morgan AM; Wachter F; Bird GH; Kugener G; Oberlick EM; Rees MG; Tiv HL; Hwang JH; Walsh KH; Cook A; Krill-Burger JM; Tsherniak A; Gokhale PC; Park PJ; Stegmaier K; Walensky LD; Hahn WC; Roberts CWM
    Cancer Res; 2019 May; 79(9):2404-2414. PubMed ID: 30755442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network.
    Toledo F; Krummel KA; Lee CJ; Liu CW; Rodewald LW; Tang M; Wahl GM
    Cancer Cell; 2006 Apr; 9(4):273-85. PubMed ID: 16616333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the antitumor effects of an MDM2 inhibitor, nutlin-3, in feline lymphoma cell lines with or without p53 mutation.
    Mochizuki H; Goto-Koshino Y; Sato M; Fujino Y; Ohno K; Tsujimoto H
    Vet Immunol Immunopathol; 2012 Jun; 147(3-4):187-94. PubMed ID: 22578852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
    Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
    Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
    Toledo F; Wahl GM
    Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leveraging the multivalent p53 peptide-MdmX interaction to guide the improvement of small molecule inhibitors.
    Cheng X; Chen R; Zhou T; Zhang B; Li Z; Gao M; Huang Y; Liu H; Su Z
    Nat Commun; 2022 Feb; 13(1):1087. PubMed ID: 35228542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas.
    Bozzi F; Conca E; Laurini E; Posocco P; Lo Sardo A; Jocollè G; Sanfilippo R; Gronchi A; Perrone F; Tamborini E; Pelosi G; Pierotti MA; Maestro R; Pricl S; Pilotti S
    Lab Invest; 2013 Nov; 93(11):1232-40. PubMed ID: 24018792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells.
    Endo S; Yamato K; Hirai S; Moriwaki T; Fukuda K; Suzuki H; Abei M; Nakagawa I; Hyodo I
    Cancer Sci; 2011 Mar; 102(3):605-13. PubMed ID: 21205074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mdm2 and Mdm4 loss regulates distinct p53 activities.
    Barboza JA; Iwakuma T; Terzian T; El-Naggar AK; Lozano G
    Mol Cancer Res; 2008 Jun; 6(6):947-54. PubMed ID: 18567799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of MDM2-p53 and MDM4-p53 protein-protein interactions small molecule dual inhibitors.
    Espadinha M; Lopes EA; Marques V; Amaral JD; Dos Santos DJVA; Mori M; Daniele S; Piccarducci R; Zappelli E; Martini C; Rodrigues CMP; Santos MMM
    Eur J Med Chem; 2022 Nov; 241():114637. PubMed ID: 35961068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.